175 related articles for article (PubMed ID: 31757303)
1. Combination Intravesical Therapy.
Brooks NA; O'Donnell MA
Urol Clin North Am; 2020 Feb; 47(1):83-91. PubMed ID: 31757303
[TBL] [Abstract][Full Text] [Related]
2. Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG.
Steinberg RL; Packiam VT; Thomas LJ; Brooks N; Vitale A; Mott SL; Crump T; Wang J; DeWolf WC; Lamm DL; Kates M; Hyndman ME; Kamat AM; Bivalacqua TJ; Nepple KG; O'Donnell MA
Urol Oncol; 2022 Jan; 40(1):9.e1-9.e7. PubMed ID: 34092482
[TBL] [Abstract][Full Text] [Related]
3. SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin.
Skinner EC; Goldman B; Sakr WA; Petrylak DP; Lenz HJ; Lee CT; Wilson SS; Benson M; Lerner SP; Tangen CM; Thompson IM
J Urol; 2013 Oct; 190(4):1200-4. PubMed ID: 23597452
[TBL] [Abstract][Full Text] [Related]
4. Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure.
Sternberg IA; Dalbagni G; Chen LY; Donat SM; Bochner BH; Herr HW
J Urol; 2013 Nov; 190(5):1686-91. PubMed ID: 23665400
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of Bacillus Calmette-Guerin refractory superficial bladder cancer: further intravesical therapy].
Kohjimoto Y; Iba A; Shintani Y; Uekado Y; Shinka T
Hinyokika Kiyo; 2005 Aug; 51(8):533-8. PubMed ID: 16164269
[TBL] [Abstract][Full Text] [Related]
6. The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial.
Gontero P; Oderda M; Mehnert A; Gurioli A; Marson F; Lucca I; Rink M; Schmid M; Kluth LA; Pappagallo G; Sogni F; Sanguedolce F; Schiavina R; Martorana G; Shariat SF; Chun F
J Urol; 2013 Sep; 190(3):857-62. PubMed ID: 23545101
[TBL] [Abstract][Full Text] [Related]
7. Salvage therapeutic strategies for bacillus Calmette-Guerin failure.
Hassler MR; Shariat SF; Soria F
Curr Opin Urol; 2019 May; 29(3):239-246. PubMed ID: 30762670
[TBL] [Abstract][Full Text] [Related]
8. Intravesical gemcitabine for non-muscle invasive bladder cancer.
Jones G; Cleves A; Wilt TJ; Mason M; Kynaston HG; Shelley M
Cochrane Database Syst Rev; 2012 Jan; 1():CD009294. PubMed ID: 22259002
[TBL] [Abstract][Full Text] [Related]
9. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
[TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of recurrence rates between intravesical gemcitabine and bacillus Calmette-Guérin induction therapy following transurethral resection of bladder tumors in patients with intermediate- and high-risk bladder cancer: A retrospective multicenter study.
Choi J; Kim KH; Kim HS; Yoon HS; Kim JH; Kim JW; Lee YS; Choi SY; Chang IH; Ko YH; Song W; Jeong BC; Nam JK
Investig Clin Urol; 2024 May; 65(3):248-255. PubMed ID: 38714515
[TBL] [Abstract][Full Text] [Related]
11. [Nonmuscle-invasive bladder cancer (NMIBC): when to perform cystectomy?].
Lebret T
Prog Urol; 2008 May; 18 Suppl 5():S111-4. PubMed ID: 18585632
[TBL] [Abstract][Full Text] [Related]
12. Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy.
Barlow LJ; McKiernan JM; Benson MC
J Urol; 2013 Mar; 189(3):834-9. PubMed ID: 23123371
[TBL] [Abstract][Full Text] [Related]
13. Experience with Sequential Intravesical Gemcitabine and Docetaxel as Salvage Therapy for Non-Muscle Invasive Bladder Cancer.
Velaer KN; Steinberg RL; Thomas LJ; O'Donnell MA; Nepple KG
Curr Urol Rep; 2016 May; 17(5):38. PubMed ID: 26968418
[TBL] [Abstract][Full Text] [Related]
14. Enhanced antitumor effect of coincident intravesical gemcitabine plus BCG therapy in an orthotopic bladder cancer model.
Horinaga M; Fukuyama R; Iida M; Yanaihara H; Nakahira Y; Nonaka S; Deguchi N; Asakura H
Urology; 2010 Nov; 76(5):1267.e1-6. PubMed ID: 21056277
[TBL] [Abstract][Full Text] [Related]
15. Updates on the use of intravesical therapies for non-muscle invasive bladder cancer: how, when and what.
Peyton CC; Chipollini J; Azizi M; Kamat AM; Gilbert SM; Spiess PE
World J Urol; 2019 Oct; 37(10):2017-2029. PubMed ID: 30535583
[TBL] [Abstract][Full Text] [Related]
16. Is gemcitabine an option in BCG-refractory nonmuscle-invasive bladder cancer? A single-arm prospective trial.
Perdonà S; Di Lorenzo G; Cantiello F; Damiano R; De Sio M; Masala D; Bruni G; Gallo L; Federico P; Quattrone C; Pizzuti M; Autorino R
Anticancer Drugs; 2010 Jan; 21(1):101-6. PubMed ID: 19858710
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of intravesical bacillus Calmette-Guérin plus interferon α-2b therapy for nonmuscle invasive bladder cancer in patients with prosthetic devices.
Rosevear HM; Lightfoot AJ; Nepple KG; O'Donnell MA
J Urol; 2010 Nov; 184(5):1920-4. PubMed ID: 20846678
[TBL] [Abstract][Full Text] [Related]
18. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
[TBL] [Abstract][Full Text] [Related]
19. The Timing of Radical Cystectomy for bacillus Calmette-Guérin Failure: Comparison of Outcomes and Risk Factors for Prognosis.
Haas CR; Barlow LJ; Badalato GM; DeCastro GJ; Benson MC; McKiernan JM
J Urol; 2016 Jun; 195(6):1704-9. PubMed ID: 26807928
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder.
Dalbagni G; Russo P; Sheinfeld J; Mazumdar M; Tong W; Rabbani F; Donat MS; Herr HW; Sogani P; dePalma D; Bajorin D
J Clin Oncol; 2002 Aug; 20(15):3193-8. PubMed ID: 12149290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
